Common questions
Retatrutide FAQ: direct, cited answers.
The questions readers ask most, answered plainly from the trial and regulatory record — investigational status kept in plain view.
How does retatrutide compare to a dual GLP-1/GIP agonist in Phase 3 studies?
A 2025 meta-analysis of three randomized trials (878 patients) put retatrutide's mean weight difference at -14.33% versus placebo [13], and mechanistically it adds a glucagon receptor arm a dual agonist lacks [3]. A direct head-to-head Phase 3 trial against a dual GIP/GLP-1 agonist is underway but has not yet reported.
What cardiovascular and kidney outcomes is retatrutide being evaluated for in Phase 3?
Dedicated cardiovascular- and kidney-outcome trials are part of the Phase 3 program (NCT06383390 [17]; TRANSCEND-CKD [23]). Incretin reviews describe renoprotective signals in type 2 diabetes and obesity [9], while class mechanistic work notes cAMP-mediated cardiac contractile effects that long-term outcome data are still needed to characterize [10].
What did the Phase 2 trial find about retatrutide dose escalation from 2 mg to 12 mg?
The 48-week Phase 2 obesity trial used stepwise escalation across 1, 4, 8, and 12 mg once weekly. The 12 mg arm reached a mean -24.2% body-weight change versus -2.1% with placebo, with dose-related gastrointestinal adverse events that the escalation schedule was designed to manage [1].
What does retatrutide do?
Retatrutide is a single-molecule triple agonist that activates the GLP-1, GIP, and glucagon receptors at once [3]. A 2025 review synthesizes its Phase 1/2 data, characterizing the up-to ~24% weight loss at 12 mg over 48 weeks as a step-change versus prior incretin therapies [6].
How does retatrutide work?
Cryo-EM structures show retatrutide engaging the GLP-1, GIP, and glucagon receptors as one peptide [3]. The GLP-1/GIP arms suppress appetite and improve glucose-dependent insulin secretion, while controlled glucagon activation adds energy expenditure and hepatic fat handling [6].
How to reconstitute retatrutide?
There is no approved formulation, storage, or reconstitution standard for retatrutide — it has been studied only as a controlled clinical-trial investigational product given by once-weekly subcutaneous injection. This is research context, not preparation instructions.
Is retatrutide FDA approved?
No. As of 2026 retatrutide is investigational, in Phase 3 clinical trials (Eli Lilly), and not approved by the FDA or any other regulator. Its efficacy and safety figures come from trials, not approved labeling [1][6].
When will retatrutide be available?
There is no approved product. Availability depends on completion of the ongoing Phase 3 TRIUMPH program (NCT05929066 [20], among others) and subsequent regulatory review, which has not occurred as of 2026. On retatrutide availability, access has been limited to clinical trials.
How to take retatrutide?
In trials, retatrutide was given as a once-weekly subcutaneous injection with stepwise dose escalation [1][4]. It is investigational with no approved dosing; this describes trial administration, not a recommendation to use it.
How long does retatrutide take to work?
Trial data describe reduced appetite and progressive weight loss over weeks of once-weekly dosing, with the largest Phase 2 body-weight changes accruing across the 36–48 week treatment periods [1][2].
Is retatrutide better than tirzepatide?
No controlled head-to-head trial has been published; a dedicated active-comparator Phase 3 study is underway [7]. Across separate trials, retatrutide's triple-agonist Phase 2 weight-loss figures are numerically large [1], but cross-trial comparison is not a substitute for a direct trial.
How much retatrutide per week?
Trials studied once-weekly subcutaneous doses from roughly 0.5 mg up to 12 mg with escalation [1][4]. This is the studied research range, not a recommended human dose; retatrutide is investigational and unapproved.
How to mix retatrutide with bacteriostatic water?
No approved preparation standard exists; retatrutide was supplied as a controlled clinical-trial product. Gray-market research-labeled material is unregulated and of unverified identity, purity, and sterility. This is regulatory context, not mixing instructions.
How to switch from tirzepatide to retatrutide?
There is no established clinical protocol for switching between these agents outside a trial; retatrutide is investigational and unapproved, and a head-to-head study is still ongoing [7].
Is retatrutide a GLP-3?
No. The informal 'GLP-3' label is not an official pharmacological class. Retatrutide is accurately described as a GIP/GLP-1/glucagon receptor triple agonist — a 'GGG' tri-agonist — confirmed by cryo-EM structural work [3].
Is retatrutide available?
Not as an approved product. Access has been limited to clinical trials; there is no lawful prescription or consumer product for retatrutide as of 2026.
What is retatrutide used for?
In trials it has been studied for obesity and type 2 diabetes [1][2], with additional Phase 2 investigation in metabolic dysfunction-associated steatotic liver disease [5] and in weight-linked comorbidities such as obstructive sleep apnea and knee osteoarthritis [14], plus ongoing cardiovascular and kidney-outcome studies [17].
What receptors does retatrutide target?
Three class-B G-protein-coupled receptors: the GLP-1 receptor, the GIP receptor, and the glucagon receptor, engaged by a single acylated peptide as confirmed by cryo-EM structural studies [3].
Is retatrutide legal?
Retatrutide is an unapproved investigational drug; it is not authorized for sale or human use outside a clinical trial. Gray-market research-labeled material sits outside any regulatory oversight.
How often do you take retatrutide?
Trials used once-weekly subcutaneous administration, supported by an approximately six-day elimination half-life measured in the first-in-human Phase 1b study [4].
What is the half-life of retatrutide?
The first-in-human Phase 1b trial reported an approximately six-day half-life, which supports once-weekly subcutaneous dosing [4].
How to store retatrutide?
No approved storage standard exists; retatrutide has only been handled as a controlled clinical-trial investigational product. This is regulatory context, not storage instructions.